News & Events
September 10, 2019 8:45 AM EDT : 21st Annual Global Investment Conference, Sponsored by H.C. Wainwright
Event Date: September 10, 2019
READ MORECrinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will present an overview of...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics...
READ MORECrinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
“The NIH SBIR program awards grant funding to proposals that are both innovative and have the potential for significant impact,...
READ MORECrinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
“Stephanie’s extensive experience with the regulatory approval process, launch and commercialization of rare and orphan disease products makes her a...
READ MORECrinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
“Crinetics is dedicated to building a pipeline of novel therapeutics for rare endocrine diseases and endocrine-related tumors. We are excited...
READ MORECrinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Looking forward to the remainder of the year, we will continue enrolling the ACROBAT trials and will initiate our Phase...
READ MORECrinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
“The first patients receiving CRN00808 in these trials marks another important milestone in advancing this novel drug candidate for the...
READ MORECrinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
Crinetics is pleased to welcome Gina to the management team, where she brings 20 years of life sciences and pharmaceuticals...
READ MORECrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
The company’s lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.